Silversun Healthcare Review

Overview

Silversun Healthcare is a telehealth platform founded around 2020 that offers GLP-1 weight management services alongside other health programs under physician oversight. The platform operates on an asynchronous care model, processing patient intake and issuing prescriptions without requiring scheduled video appointments.

Silversun sits in the broader field of independent GLP-1 telehealth platforms that expanded rapidly between 2021 and 2024 to serve demand for weight management medications. Its positioning and specific service details are not widely covered in independent healthcare or consumer media as of April 2026.

Transparency note: Silversun Healthcare has a limited public footprint. Independent reviews, third-party coverage, and verifiable clinical details are sparse. This profile is based on publicly available information only. Before enrolling with any smaller telehealth platform, patients should verify physician licensing in their state, confirm the dispensing pharmacy's accreditation and state licensure, and request information about the platform's clinical oversight model. Verify all program details at silversunhealthcare.com.

April 2026 regulatory context: The FDA's enforcement actions against compounded semaglutide and tirzepatide create direct uncertainty for platforms that have relied on compounded GLP-1 formulations. Semaglutide was removed from the FDA's drug shortage list in early 2026, restricting the legal basis for 503A and many 503B compounding pharmacies to produce it. Patients considering Silversun should ask directly whether current prescriptions are compounded or branded, and confirm pharmacy compliance before filling any prescription.

Medications Offered

Silversun Healthcare's current formulary is not publicly confirmed. The platform likely prescribes GLP-1 medications including semaglutide and/or tirzepatide, but whether these are compounded or branded versions, and which specific products are currently available, should be verified directly at silversunhealthcare.com.

Orforglipron (the first oral GLP-1 receptor agonist) has not received FDA approval as of April 2026 (PDUFA date: April 10, 2026) and is not available through any telehealth platform.

Pricing

Pricing details are not independently confirmed. Verify current rates, billing structure, and what is included in the program fee at silversunhealthcare.com.

States Served

Telehealth prescribing availability is limited to states where Silversun's licensed providers are authorized to practice. Verify which states are currently served at silversunhealthcare.com before starting intake.

Insurance

GLP-1 insurance coverage depends on your specific health plan, the medication prescribed, and your diagnosed indication. Silversun Healthcare's insurance acceptance status is not publicly confirmed — verify at silversunhealthcare.com.

Consultation Process

1. Visit silversunhealthcare.com and complete the online intake form.
2. Provide your health history, current medications, weight history, and relevant comorbidities.
3. A licensed physician reviews your intake asynchronously.
4. If you qualify, a prescription is issued and sent to a partner pharmacy.
5. Medication is shipped to your address (confirm shipping state eligibility at enrollment).
6. Ongoing medication management — including dose adjustments and provider check-ins — is handled through the platform. Confirm cadence and format before enrolling.

Pros

• Async model reduces scheduling friction and may provide faster access to a prescription than synchronous platforms
• GLP-1 offerings address a high-demand category with demonstrated clinical efficacy
• Founded in 2020, giving it several years of operational experience relative to newer entrants

Cons

• Very limited independent reviews and third-party coverage make clinical quality difficult to assess
• Compounding regulatory environment in April 2026 creates real uncertainty about medication availability and legal standing
• Physician licensing, pharmacy accreditation, and clinical oversight model are not prominently disclosed — patients must ask directly
• Smaller platforms carry higher operational risk (service interruption, formulary changes) compared to well-capitalized providers

Best For

Patients exploring GLP-1 telehealth options who are willing to perform direct due diligence on a smaller platform. Not recommended as a first choice for patients with complex medical histories or those who prioritize independent reviews and established brand credibility. If considering Silversun, verify physician credentials, pharmacy licensing, and current medication availability before committing.

Editorial Verdict

Silversun Healthcare operates in a high-demand space, but its limited public footprint means independent editorial assessment is thin. Care quality, provider credentials, and medication supply chain compliance are not verifiable from publicly available information alone. Before enrolling, confirm that prescribing physicians are licensed in your state, that the dispensing pharmacy is accredited and compliant with current FDA compounding rules, and check for any disciplinary history on your state medical board's website. Silversun may be fine — but the due diligence burden falls on the patient. Verify all current program details at silversunhealthcare.com.

Related Content

• How Much Does Semaglutide Cost?
• How Much Does Tirzepatide Cost?
• Who Qualifies for GLP-1 Medications?
• Mochi Health vs. Henry Meds